Samsung Bioepis and Hanmi Pharmaceutical will jointly sell the osteoporosis treatment Prolia biosimilar (a copy of a biopharmaceutical) in the domestic market. Samsung Bioepis, the developer of the drug, will be responsible for production and supply, while both companies will handle domestic marketing and sales activities together.
The two companies announced on the 19th that they held a joint sales agreement signing ceremony for the domestic launch of the osteoporosis treatment Prolia biosimilar (active ingredient denosumab) on the 18th at Hanmi Pharmaceutical's headquarters, Park Hall. Samsung Bioepis is currently undergoing the approval process for the Prolia biosimilar in the domestic market, while it obtained approval in the United States and Europe in February.
The original drug Prolia is an osteoporosis treatment developed by Amgen, which had a global revenue of approximately 6.5 trillion won in 2024 and a domestic market revenue of about 174.9 billion won. The project name for the Prolia biosimilar developed by Samsung Bioepis is SB16.
The two companies stated that they plan to establish a close cooperative relationship in order to offer patients the opportunity to receive biopharmaceuticals at more reasonable prices.
Kim Kyung-a, president of Samsung Bioepis, said, "Through this contract, we will closely cooperate based on our development capabilities and the sales and marketing expertise of Hanmi Pharmaceutical so that domestic patients can experience more benefits through biosimilar prescriptions."
Park Jae-hyun, president of Hanmi Pharmaceutical, said, "Hanmi Pharmaceutical is a prepared partner that has already established its presence in the musculoskeletal treatment market and has secured differentiated, evidence-based marketing capabilities," and added, "Through this partnership, we will create innovative results that allow both companies to grow together and continue close cooperation."